Supramolecular PEGylation of biopharmaceuticals
Name
Webber-2016-Supramolecular PEGylation of bioph.pdf
Size
1.09 MB
Format
Adobe PDF
Checksum (MD5)
e5a5b925f5d7c8a619a8be8c4cc682b5
Author(s)
Vinciguerra, Brittany
Thapa, Lavanya S.
Jhunjhunwala, Siddharth
Isaacs, Lyle
Webber, Matthew
Appel, Eric
Cortinas, Abel Bryan
Langer, Robert S
Anderson, Daniel Griffith
Date Issued
November 2016
Journal
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences (U.S.)
Citation
Webber, Matthew J. et al. “Supramolecular PEGylation of Biopharmaceuticals.” Proceedings of the National Academy of Sciences 113, 50 (December 2016): 14189–14194 © 2016 National Academy of Sciences
Version
Final published version
Abstract
The covalent modification of therapeutic biomolecules has been broadly explored, leading to a number of clinically approved modified protein drugs. These modifications are typically intended to address challenges arising in biopharmaceutical practice by promoting improved stability and shelf life of therapeutic proteins in formulation, or modifying pharmacokinetics in the body. Toward these objectives, covalent modification with poly(ethylene glycol) (PEG) has been a common direction. Here, a platform approach to biopharmaceutical modification is described that relies on noncovalent, supramolecular host–guest interactions to endow proteins with prosthetic functionality. Specifically, a series of cucurbit[7]uril (CB[7])–PEG conjugates are shown to substantially increase the stability of three distinct protein drugs in formulation. Leveraging the known and high-affinity interaction between CB[7] and an N-terminal aromatic residue on one specific protein drug, insulin, further results in altering of its pharmacological properties in vivo by extending activity in a manner dependent on molecular weight of the attached PEG chain. Supramolecular modification of therapeutic proteins affords a noncovalent route to modify its properties, improving protein stability and activity as a formulation excipient. Furthermore, this offers a modular approach to append functionality to biopharmaceuticals by noncovalent modification with other molecules or polymers, for applications in formulation or therapy.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1616639113
